RE: RE: Stock PriceThose are good questions. Net, net, I really don't know. But here are some considerations:
Timing may be an easier aspect to guage. I firmly believe that serious talks have already started with potential commercial partners. I have no direct knowledge, but it makes sense to me. The 2b clinical had about 100 people so the data compilation and analysis should not take too long. An appropriate start dosage for marketing has been identified and side effects are zero. Maybe they will even comsider going for NDA at thsi point.
I think Protox might prefer a licensing deal with a niche player, but the wild card is the cancer work, which would attract the big boys. My guess on timing...by year end...maybe early 2010. I think it is 50/50 licensing partnership versus buyout.
As to price, the BPH market size a major issue that would drive the near-term value. I'm going to try to get a handle on this next week. Maybe even more important on value is the early progress/results on prostate and brain cancer. Remember that nothing much has been released on this work and it is now back-burnered so that work on BPH could be completed. That was a brilliant strategy...but it may be a key point in PRX value as I understand that the basic science is related to prx302. As much as anything, the BPH study may have established credibility of the science. That would truly enhance value.
I'd like to hear other thoughts on your questions.
Cheers. Think I'll go for a drive.
jb